XML 25 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Earnings
Noncontrolling Interest
Total
Beginning balance at Dec. 25, 2021 $ 61,902 $ 243,995 $ 1,678,121 $ (5,405) $ 37,956 $ 2,016,569
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     692,651   12,210 704,861
Foreign currency translation adjustment       (1,841) 1,802 (39)
Unrealized (loss) gain on investments and other       (1,829)   (1,829)
Distributions to NCI         (12,024) (12,024)
Contributions to NCI         538 538
Redeemable NCI         (7,641) (7,641)
Cash dividends     (58,860)     (58,860)
Issuance of shares under ESPP 44 2,725       2,769
Issuance/net forfeitures of shares under stock grant programs 806 9,919 25     10,750
Issuance of shares under deferred compensation plans 113 (113)        
Repurchase of shares (1,247)   (94,527)     (95,774)
Expense associated with share-based compensation arrangements   27,987       27,987
Accrued expense under deferred compensation plans   9,516       9,516
Ending balance at Dec. 31, 2022 61,618 294,029 2,217,410 (9,075) 32,841 2,596,823
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     514,312   663 514,975
Foreign currency translation adjustment       9,762 4,267 14,029
Unrealized (loss) gain on investments and other       419   419
Distributions to NCI         (7,355) (7,355)
Other   817     (930) (113)
Purchase of remaining NCI of subsidiary   (1,210)     (917) (2,127)
Cash dividends     (68,238)     (68,238)
Issuance of shares under ESPP 33 2,717       2,750
Issuance/net forfeitures of shares under stock grant programs 821 14,485 22     15,328
Issuance of shares under deferred compensation plans 124 (124)        
Repurchase of shares (975)   (81,174)     (82,149)
Expense associated with share-based compensation arrangements   34,727       34,727
Accrued expense under deferred compensation plans   10,895       10,895
Ending balance at Dec. 30, 2023 61,621 354,702 2,582,332 1,106 30,429 3,030,190
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     414,560   5,413 419,973
Foreign currency translation adjustment       (16,428) (3,441) (19,869)
Unrealized (loss) gain on investments and other       11   11
Distributions to NCI         (11,848) (11,848)
Other   242       242
Purchase of remaining NCI of subsidiary   8,400       8,400
Cash dividends     (80,782)     (80,782)
Issuance of shares under ESPP 28 2,784       2,812
Issuance/net forfeitures of shares under stock grant programs 380 5,923 77     6,380
Issuance of shares under deferred compensation plans 104 (104)        
Repurchase of shares (1,409) (17,686) (140,907)     (160,002)
Expense associated with share-based compensation arrangements   37,938       37,938
Accrued expense under deferred compensation plans   11,664       11,664
Ending balance at Dec. 28, 2024 $ 60,724 $ 403,379 $ 2,775,280 $ (15,311) $ 20,553 $ 3,244,625